Metagenomi, Inc. 8-K

What Happened

• Metagenomi, Inc. filed a Certificate of Amendment to change its corporate name to Metagenomi Therapeutics, Inc., effective at 12:01 a.m. Pacific Time on January 12, 2026. The Board approved the change under Section 242 of Delaware law; no stockholder vote was required and the change does not affect stockholder rights.
• The Board also amended and restated the company’s bylaws solely to reflect the new corporate name. The company furnished a press release and a January 2026 corporate presentation with the 8-K; the filing is signed by President and CEO Jian Irish, Ph.D., M.B.A.

Key Details

• Name change effective: January 12, 2026 at 12:01 a.m. PT.
• Trading symbol remains: MGX on The Nasdaq Global Select Market.
• CUSIP number: unchanged.
• Bylaws: amended and restated only to reflect the new name; no other bylaw changes.

Why It Matters

• For investors, this is primarily a corporate rebranding and legal name change—no change to share rights, trading symbol, or CUSIP, and no shareholder vote was required.
• The company’s public materials (press release and corporate presentation) were filed with the 8-K, providing additional context on the name change and business updates for investors to review.